Skip to main content

Table 2 Baseline Clinical Characteristics

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 Number of participants, N (%)
Placebo(N = 102)DNX 5 mg (N = 102)DNX 10 mg (N = 103)DNX 25 mg (N = 103)DNX 35 mg (N = 102)DNX 50 mg (N = 102)
Current smoker39 (38)40 (39)37 (36)35 (34)38 (37)36 (35)
Former smoker63 (62)62 (61)66 (64)68 (66)64 (63)66 (65)
SGRQ
 Q1 (I cough) most days a week or several days a week80 (79)86 (85)74 (73)80 (78)78 (76)82 (81)
 Q2 (I bring up phlegm) most days a week or several days a week82 (81)80 (79)65 (64)81 (79)77 (75)80 (79)
Chronic mucus hypersecretion (CMH)a
 CMH+75 (74)76 (75)58 (57)75 (74)68 (67)73 (72)
 CMH-26 (26)25 (25)43 (43)27 (26)34 (33)28 (28)
E-RS: COPD total score
  < 1037 (36)35 (34)42 (41)44 (43)37 (36)45 (44)
  ≥ 1065 (64)67 (66)60 (59)59 (57)65 (64)57 (56)
CAT score
  < 1013 (13)11 (11)14 (14)14 (14)8 (8)9 (9)
  ≥ 1088 (87)90 (89)87 (86)85 (86)93 (92)91 (91)
Exacerbation history:
  Moderate/severe
 115 (15)19 (19)26 (25)17 (17)11 (11)22 (22)
  ≥ 287 (85)83 (81)76 (74)86 (83)91 (89)80 (78)
Medications
 ICS + LABA + LAMA39 (38)44 (43)45 (44)43 (42)39 (38)40 (39)
 LABA + LAMA24 (24)23 (23)30 (29)20 (19)21 (21)34 (33)
 ICS + LABA19 (19)20 (20)19 (18)27 (26)25 (25)15 (15)
 LAMA11 (11)7 (7)4 (4)8 (8)10 (10)5 (5)
Inflammatory markers
 CRP (mg/L)5.6 (9.4)7.2 (23.8)7.1 (15.1)8.0 (17.5)4.3 (5.0)5.5 (8.1)
 Fibrinogen (g/L)3.3 (0.9)3.4 (1.0)3.4 (0.9)3.4 (0.8)3.3 (0.8)3.4 (0.8)
  1. aA subject is considered CMH+ if baseline SGRQ Q1 and Q2 = Most or several days a week.